Menu
Recruiting NCT07222280

Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy

No phase Interventional Alzheimer Dementia Alzheimer Disease Delirium Confusional State Encephalopathy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Quest AD-Detect blood test.
Who it may be relevant to
Registry conditions: Alzheimer Dementia, Alzheimer Disease, Delirium Confusional State, Encephalopathy. Basic parameters: 60 years — 90 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The goal of this clinical trial is to determine if utilizing the Quest AD-Detect blood test, while patient's are hospitalized for a cognitive diagnosis (such as delirium or encephalopathy), will result in an earlier diagnosis of underlying Alzheimer's disease. * Will this blood test have the ability to distinguish between Alzheimer's disease and other causes of cognitive impairment in the inpatient setting? * Neurology Clinic will complete a 6-month post-hospitalization follow up with patients who have had the Quest AD-Detect Alzheimer's Disease blood test completed while they were inpatient to discuss the risk assessment portfolio

Interventions

  • Diagnostic test Quest AD-Detect blood test
    Blood will be collected and sent for testing using the Quest AD-Detect blood test

Primary outcome measures

  • To show the percentage of patients (21 patients in the study) who presented with a cognitive diagnosis (including but not limited to delirium, encephalopathy, etc.) that have a positive biomarker for Alzheimer's dementia [Time frame: From enrollment to 6 month follow up appointment with Neurology Clinic.]

Eligibility criteria

Inclusion criteria

  • Ages 60 to 90 years old
  • No prior diagnosis of dementia
  • Currently hospitalized with cognitive diagnosis, including but no limited to; delirium, encephalopathy, etc. thought to be secondary to a toxic/metabolic state

Exclusion criteria

  • Age under 60 years
  • Prior diagnosis of dementing illness or other organic etiology to cognitive impairment

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Diagnostic

Study locations

United States · 6 centers
  • Cumberland Medical Center — Crossville
  • Roane Medical Center — Harriman
  • Fort Sanders Regional Medical Center — Knoxville
  • Fort Loudon Medical Center — Lenoir City
  • Methodist Medical Center — Oak Ridge
  • LeConte Medical Center — Sevierville

Identifiers

NCT: NCT07222280 · ADUE2025

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗